cGMP manufacturing
BRC’s facility grows plants and processes botanical raw materials using GMP-compliant procedures for extraction and formulation.

Pharmaceutical manufacturer and researcher specializing in cannabis-based plant therapeutics and USDA-compliant THC testing.
brctherapeutics.comCrawled Nov 18, 2026
BRC’s facility grows plants and processes botanical raw materials using GMP-compliant procedures for extraction and formulation.
BRC-001 as a potential treatment addressing joint inflammation and pain in AIIA.
BRC-002 as a potential treatment addressing pain and other symptoms in CRPS.
BRC is using a multimodal approach towards multimechanistic diseases and conditions.
The company advances clinical candidates for AIIA and CRPS.
BMC Plant Biology Mahboubeh Mostafaei Dehnavi, Annabelle Damerum, Sadegh Taheri, Ali Ebadi, Shadab Panahi, George Hodgin, Brian Brandley, Seyed Alireza Salami & Gail Taylor.
BRC’s R&D team members have a long history of publishing data relating to cannabinoids and translational science.
The company manufactures drug substances by extracting, isolating, and processing them, then shipping to research partners, clinical trial sites, formulators, biotech companies, and pharma companies.
Exp Clin Psychopharmacol. Zvorsky I, Kulpa J, Mechtler LL, Ralyea CC, Lombardo J, Del Re AC, Bonn-Miller MO.
Scientists at City of Hope are testing a pharmaceutical-grade cannabis-based medicine to determine whether it is effective in treating joint pain in breast cancer patients taking aromatase inhibitors
tThe federal government is preparing to award the first new licenses for cultivating cannabis for scientific research, giving U.S. marijuana operators a crack at entering a business that has been dominated by the University of Mississippi for more than 50 years.
The DEA is finalizing the effort to increase the number of permitted research-grade marijuana growers after initially receiving guidance from its own administrative law judge in February 2007.
Clinical testing ongoing. Regulatory interactions.
Clinical testing ongoing. Regulatory interactions.
BRC Therapeutics has access to a renowned group of advisors from all relevant disciplines.
BRC Therapeutics has access to a renowned group of advisors from all relevant disciplines.
Board members have experience in finance, medicine, and drug development.
The company has expertise in all aspects of drug development and manufacturing, with specialized knowledge of botanically derived drug products.
The company’s board members have combined experience in finance, medicine, and drug development.
The company has experience across all aspects of drug development and manufacturing, with knowledge of botanically derived drug products.
BRC focuses on regulated cannabinoid therapeutics to address unmet medical needs, maintaining DEA compliance for botanically derived medicines.
BRC Therapeutics aims to address unmet medical needs using regulated cannabinoid therapeutics and maintains DEA compliance for botanically derived medicines.
BRC Therapeutics’ privacy policy describes how it handles personal data, users’ privacy rights, and legal protections.
BRC Therapeutics develops novel therapies for serious or life-threatening diseases, aiming for regulatory approval to address unmet medical needs.
BRC Therapeutics’ terms and conditions govern access to and use of its website, related subdomains, sites, services, and tools.